AMD

The Choroid in AMD: A Critical Point of Failure?

Advancements in imaging and new computational models 
are improving our understanding of choroidal failure. 

The ‘Switch’ and Macular Atrophy in nAMD

New insights into how frequent, long-term anti-VEGF injections 
and a change in medication impact RPE loss. 

Answers to the Three Big Questions of Long-Term Treatment of Wet AMD

Anti-VEGF agents have forced us to choose an agent and regimen, and learn when enough is enough.

Retina Report from ARVO 2016

A closer look at five abstracts on VMT, DME, AMD, OCT and gene therapy.

TAE for Wet AMD: Practical Tips from the Pros

A conversation on the nuances of implementing treat and extend.

Subclinical MNV: Do We Watch or Treat?

Now that we have OCT-A, we can no longer ignore macular neovascularization in non-exudative AMD.

Big Data and AMD Progression

Gathering and analyzing imaging biomarkers from SD-OCT along with other inputs can aid in tracking patients.

Dry AMD Progression in Wet AMD

What we know and don’t know about geographic atrophy.

A Quick Look at CHROMA, SPECTRI

Lead investigator provides details on parallel trials of lampalizumab.

Can Anti-VEGF Cause GA in Wet AMD?

A host of trials are trying to answer this question. Here’s what they’ve found so far.